Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the Grupo Ginecologico Español para el Tratamiento Oncologico (GGETO)

Eur J Cancer. 1991;27(7):864-6. doi: 10.1016/0277-5379(91)90135-z.

Abstract

27 patients with FIGO stage III-IV endometrial adenocarcinoma were entered in a phase II trial evaluating activity and safety of epirubicin given at 80 mg/m2 intravenously every 3 weeks. 2 complete remissions (including a pathological one) and 5 partial responses were observed for a response rate of 26% (95% confidence interval 11-46). The median time to progression and median survival for all treated patients was 6 and 9.5 months, respectively. Treatment was well tolerated. Haematological toxicity was mild. The median total cumulative dose of epirubicin was 480 mg/m2 (160-880) and cardiac toxicity was not observed. Further studies with higher doses of epirubicin in combination with other active drugs are indicated.

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / mortality
  • Adenocarcinoma / pathology
  • Adult
  • Aged
  • Drug Evaluation
  • Endometrium / pathology
  • Epirubicin / adverse effects
  • Epirubicin / therapeutic use*
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Uterine Neoplasms / drug therapy*
  • Uterine Neoplasms / mortality
  • Uterine Neoplasms / pathology
  • Vagina / pathology

Substances

  • Epirubicin